Deciphering the developmental trajectory of tissue-resident Foxp3+ regulatory T cells

Front Immunol. 2024 Mar 28:15:1331846. doi: 10.3389/fimmu.2024.1331846. eCollection 2024.

Abstract

Foxp3+ TREG cells have been at the focus of intense investigation for their recognized roles in preventing autoimmunity, facilitating tissue recuperation following injury, and orchestrating a tolerance to innocuous non-self-antigens. To perform these critical tasks, TREG cells undergo deep epigenetic, transcriptional, and post-transcriptional changes that allow them to adapt to conditions found in tissues both at steady-state and during inflammation. The path leading TREG cells to express these tissue-specialized phenotypes begins during thymic development, and is further driven by epigenetic and transcriptional modifications following TCR engagement and polarizing signals in the periphery. However, this process is highly regulated and requires TREG cells to adopt strategies to avoid losing their regulatory program altogether. Here, we review the origins of tissue-resident TREG cells, from their thymic and peripheral development to the transcriptional regulators involved in their tissue residency program. In addition, we discuss the distinct signalling pathways that engage the inflammatory adaptation of tissue-resident TREG cells, and how they relate to their ability to recognize tissue and pathogen-derived danger signals.

Keywords: Foxp3 + eTREG cells; TREG development; inflammation; mucosal immunity; polarization; tissue residency; transcriptional adaptation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmunity*
  • Forkhead Transcription Factors / metabolism
  • T-Lymphocytes, Regulatory*
  • Thymus Gland / metabolism

Substances

  • Forkhead Transcription Factors

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The funds for this study came from the Canadian Institutes of Health Research (CIHR) operating grants (MOP67211).